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Abstract Glutathione-S-transferase (GST)-pp60cSrc (GST-
Src) expressed in Escherichia coli is as catalytically active as
puri¢ed, activated pp60cSrc protein derived from human plate-
lets. We utilized the bacterially expressed enzyme, together with
information about the structures of Src family kinases in com-
plex with their inhibitors PP1 and PP2, to modify PP1 in a
quest for improved inhibitors. Despite the detailed structural
information on Hck-PP1 and Lck-PP2 complexes, which shows
that PP1 and PP2 bind to the adenosine triphosphate (ATP)
pocket, we were unable to improve the a⁄nity between modi¢ed
PP1 and Src. Puzzled, we examined in detail the mechanism by
which PP1 inhibits the kinase activity of Src. Here we report
that PP1 is non-competitive with ATP for the inhibition of Src,
at variance with what is currently accepted, and is a ‘mixed
competitive inhibitor’ vis-a'-vis the substrate. These ¢ndings
shed new light on the mechanism whereby PP1-like molecules
inhibit Src. Examination of the homology between the kinase
domain of Src and those of Hck and Lck reveals signi¢cant
di¡erences outside the ATP binding pocket, whereas they are
identical within the ATP binding domain. These results suggest
that PP1 may be a leading compound for ATP non-competitive
inhibitors of Src family kinases. Since Src in its active form is
the hallmark of numerous cancers, understanding how PP1 in-
hibits activated Src will aid in the discovery of potent and se-
lective Src kinase inhibitors.
3 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The protein tyrosine kinase pp60cSrc (Src) is a major signal
transduction element in both normal and transformed cells
[1^3]. Src contributes signi¢cantly to the transformed pheno-
type of cancer cells and functions as a survival factor in can-
cer cells [4,5]. Moreover, we recently showed that c-Src medi-
ates anti-apoptotic signals through regulation of the
expression of the anti-apoptotic gene Bcl-XL [4]. Since Src
kinase has been found to be active in many tumors [3,6^9],
Src kinase inhibitors could prove useful as anti-cancer agents
for many types of cancer. We, therefore, developed a non-
radioactive assay for screening activated c-Src kinase inhibi-
tors. We show here, for the ¢rst time, that glutathione-S-
transferase (GST)-c-Src, isolated from Escherichia coli, is as
catalytically active as activated Src isolated from human
platelets. It appears that the activation of GST-Src is medi-
ated by GST-induced trans-autophosphorylation. Utilizing
the three-dimensional model of PP1 crystallized with inactive
Hck [10], and PP2 with the activated form of the highly ho-
mologous Src kinase family member Lck [11], we probed po-
tential ‘empty’ spaces in order to ¢ll them with substituents on
PP1 or on PP2, with the aim of improving a⁄nity. In view of
the identity of the adenosine triphosphate (ATP) binding
pocket among the Src family members, we expected to suc-
ceed in obtaining improved PP1 type molecules.
Our attempt to deviate from the PP1/PP2 core is important,
particularly in view of the ¢nding that PP1 is as potent against
the platelet-derived growth factor receptor (PDGFR) kinase
as it is against Src kinase [12]. Despite the rational design,
attempts to improve on PP1/PP2 have so far met little success.
We, therefore, examined the detailed kinetic mechanism by
which PP1 inhibits active GST-Src. We found, surprisingly,
that PP1 is non-competitive vis-a'-vis ATP and is a ‘mixed
competitive’ inhibitor vis-a'-vis the substrate. These ¢ndings
shed new light on the inhibitory mechanism of PP1.
2. Materials and methods
2.1. Construction of a plasmid encoding GST-Src
A blunt-ended NcoI fragment from plasmid pVN 1.8 encoding the
neuronal c-SRC gene was ligated into the SmaI site of plasmid
pGEX2T. The construct was transformed into E. coli strain DH5K.
2.2. Puri¢cation of GST-Src protein from bacteria
E. coli DH5K carrying the GST-SRC plasmid was grown to an
optical density (600 nm) of 0.6^0.7, after which isopropyl-L-D-thio-
galactopyranoside (IPTG) (Calbiochem) was added to 0.5 mM for 2 h.
The bacteria were centrifuged at 4000Ug for 10 min, and resuspended
in 20 ml TEMB bu¡er (0.1 mM ethylenediamine tetraacetic acid
(EDTA), 20 mM Tris^HCl pH 7.5, 1 mM MgCl2, 1 mM L-mercap-
toethanol and 1% Triton X-100) containing protease inhibitors (1.5
WM aprotinin, 1 mM 4-(2-aminoethyl)-benzene sulfonyl £uoride
(AEBSF), 2 mM benzamidine, 20 WM leupeptin). The bacteria were
lysed using a high pressure French Press machine (1000 psi, twice),
and the lysate was centrifuged for 15 min at 12 000Ug at 4‡C. The
supernatant was incubated with glutathione Sepharose beads (Phar-
macia) for 30 min at 4‡C. The beads were washed with phosphate-
bu¡ered saline (PBS) and the GST-Src fusion protein was eluted with
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5 mM glutathione in 50 mM Tris pH 8, 1 mM MgCl2. The eluted
protein was kept at 370‡C until use.
2.3. Src kinase assay (enzyme-linked immunosorbent assay (ELISA))
The general tyrosine kinase substrate poly(Glu^Tyr) (4:1) (PGT,
Sigma) was coated onto 96-well Maxisorp plates (Nunc) by adding
125 Wl 0.1 mg/ml PGT in PBS to each well. Plates were sealed and
incubated for 16 h at 37‡C, washed once with TBST (10 mM Tris^
HCl pH 7.5, 50 mM NaCl and 0.1% Triton X-100), dried for 2^3 h at
37‡C and stored at 4‡C.
50 ng of puri¢ed GST-Src per well were incubated in 20 mM Tris^
HCl pH 7.5, 10 mM MgCl2 with or without inhibitors for 20 min at
30‡C.
Phosphorylation of tyrosyl residues was initiated by the addition of
20 WM ATP and terminated 10 min later by the addition of EDTA to
a ¢nal concentration of 200 mM. Plates were washed ¢ve times with
TBST and blocked with low-fat (1%) milk diluted 1:20 into TBST.
For quanti¢cation of phosphorylated tyrosines, plates were incubated
with rabbit polyclonal anti-phosphotyrosine serum for 1 h at room
temperature, washed ¢ve times, and incubated with anti-rabbit per-
oxidase-conjugated antibody for 45 min.
Detection was carried out using a color reagent, 2,2P-azido-bis
3-ethylbenzihiazoline-6-sulfonic acid (ABTS) (Sigma), in citrate-phos-
phate bu¡er pH 4 containing 0.004% H2O2. 10 min after ABTS ad-
dition the OD at 405 nm was measured.
IC50 values of inhibitors were determined using the REGRESSION
program (Blackwell Scienti¢c Software, Osney Mead, Oxford, UK).
2.4. Radioactive kinetic experiments
For competition with the substrate, parallel reactions were set up,
with PGT at various concentrations (10, 20, 40, 80,160 WM). For each
reaction, 20 ng of puri¢ed GST-Src were added to a solution contain-
ing PP1. The reactions were initiated by the addition of reaction bu¡-
er (¢nal concentration: Tris^HCl 20 mM, 10 mM MgCl2, 10 WM ATP
and 3 WCi/reaction [Q-32P]ATP). The reactions were incubated at 30‡C
for 20 min, and stopped by the addition of EDTA pH 8, 0.1 M (¢nal
concentration). Reaction samples were then absorbed onto 3 mm
Whatman paper squares. The squares were washed three times for
30 min each and twice for 1 h, in 10% TCA, 1% sodium pyrophos-
phate, at room temperature. Squares were then washed in ethanol and
dried. Radioactivity on the squares was counted by a scintillation
counter using the ‘Cherenkov’ program. The data were analyzed by
the Microsoft Excel program. IC50 values were determined using the
REGRESSION program. For competition with the substrate (ATP),
20 ng/reaction of puri¢ed GST-Src were added to a solution contain-
ing PP1 and poly(Glu^Tyr) (4:1). The reactions were initiated by the
addition of reaction bu¡er (¢nal concentration: Tris^HCl 20 mM, 10
mM MgCl2, ATP at various concentrations (5, 10, 20, 50, 100 WM)
and 3 WCi/reaction [Q-32P]ATP). The rest of the assay was conducted
as described above.
2.5. Src kinase inhibitors
PP1 and PP2 were synthesized as described by us previously [10].
3. Results and discussion
3.1. Production of bacterially active c-Src
We examined the phosphorylation state of GST-Src ex-
pressed in E. coli, and found that it was phosphorylated on
both tyrosine 419, which positively stimulates Src activity, and
on tyrosine 530, which negatively regulates Src activity (Fig.
1A). This phosphorylation is most probably due to the oligo-
merization of GST, which is known to occur (data not
shown). The puri¢ed GST-Src protein was found to phos-
phorylate denatured enolase, as well as the general tyrosine
kinase substrate poly(Glu^Tyr) (4:1). The speci¢c activity of
GST-Src, as determined by a radioactive assay, was found to
be 23 nmol/min/mg, similar to the speci¢c activity of pp60cSrc
puri¢ed from human platelets [13].
We calibrated an ELISA assay, using the general tyrosine
kinase substrate poly(Glu^Tyr) (4:1) coated on 96-well micro-
titer plates [14^17] (Fig. 1B, and data not shown). The Km of
GST-Src for ATP (Fig. 1C) is 8.55 WM, which is lower than
that of recombinant c-Src protein from baculovirus, reported
to be 30 WM [16] or 37 WM [18].
After calibration of the assay, we tested the speci¢city of
the system. Known Src and other tyrosine kinase inhibitors
were examined for their abilities to inhibit GST-Src. As ex-
pected, the known Src kinase inhibitors, PP1 and PP2 [19],
potently inhibited GST-Src activity, with IC50 values of 50
(for PP1) and 100 nM (for PP2) (Table 1). Other tyrosine
kinase inhibitors had far lower inhibitory e¡ects on GST-
Src activity than on their target kinases (Table 2).
3.2. The e⁄cacy of PP1/PP2 analogs designed on the basis of
the three-dimensional structure of Src
According to the solved structure of Src family kinases, in
complex with inhibitor PP1 [10] or PP2 [11], the binding site
of these inhibitors is located in the crevice between the N- and
C-lobes of the Src kinase domain (Fig. 2, and [10]). There are
several structures of Hck in complex with inhibitors available
in the Protein Database (PDB). These structures are of the
inactive, unphosphorylated form of the kinase domain, and
thus the two lobes are in the closed conformation. The struc-
tures include complexes with adenosine 5P-(L,Q-imido)triphos-
phate (AMP-PNP) (PDB code 1AD5), quercetin (PDB code
2HCK) [20] and PP1 (PDB code 1QCF) [10]. These structures
reveal that the pyrazolopyrimidine rings of AMP-PNP and of
PP1 in the complexes are positioned in similar orientations at
the binding site. The tuloyl group is thus located inward from
the binding pocket and the phosphate moiety of AMP-PNP
and t-butyl in PP1 is positioned towards the portal area of the
binding site. Recently, structures of the phosphorylated, open
form of the Lck kinase domain complexed with AMP-PNP,
staurosporine and PP2 (PDB codes 1QPC, 1QPD, 1QPE re-
spectively) were reported [11]. The structures of activated Lck
in complex with AMP-PNP and PP2 demonstrate, as in the
case of Hck, that the pyrazolopyrimidine ring systems of the
inhibitors are in similar orientations. Superimposition of the
Lck-AMP-PNP and Hck-AMP-PNP complexes reveals that
the pyrazolopyrimidine ring systems and the sugar moieties
are in similar orientations at the binding sites, whereas the
phospho chains adopt somewhat di¡erent conformations in
the two structures. Moreover, in the complex of Lck with
AMP-PNP, there is a 1,2-ethandiol molecule at the binding
site, which is not present in the Hck-AMP-PNP structure.
Based on structural analysis of the Lck-PP2 complex, we
can identify cavities in the binding pocket that could theoret-
ically accommodate additional structural elements attached to
the two-ring system. Examination of the homology between
Src and Hck/Lck reveals that the amino acid residues which
bind APPNHP are identical (¢g. 6 in [10]). We thus reasoned
that it was legitimate to test PP1 and its analogs on active Src.
18 rationally designed compounds were synthesized (Gazit
and Levitzki, unpublished) and examined for inhibition of
GST-Src (data not shown). Like PP1 and PP2, all of these
compounds contain the pyrazolopyrimidine structural ele-
ment, which is positioned in a consensus conformation in
both the closed (Hck-PP1, AMP-PNP) and open (Lck-PP2,
AMP-PNP) conformations of the kinase domain. Looking at
the three-dimensional structures, we probed the ‘empty’ space
near the toluyl group in PP1. We tried to ‘¢ll’ the space by
elongation of this substituting group. Contrary to our expect-
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ations, we found no compound with better e⁄cacy than PP1
or PP2 (data not shown). Similarly, attempts to improve the
a⁄nity of the inhibitor by replacing the t-butyl group also
failed (data not shown). From analysis of the results vis-a'-
vis the three-dimensional structure, it is impossible to corre-
late the experimental IC50 values (data not shown) on Src
with the structural information available for Hck-PP1 and
Lck-PP2. This is quite puzzling since the molecules, when
modeled (Fig. 2), occupy the binding site without any signi¢-
cant steric hindrance. In Fig. 2 we modeled the compound 1-
(4-carboxyphenyl)-3-(4-methylphenyl)-4-amino pyrazolo [3.4-
d] pyrimidine, which we prepared according to the spaces
‘available’, based on the structure of Lck-PP2. This com-
pound was expected to possess very good a⁄nity for c-Src,
µ
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Fig. 1. Properties of bacterial GST-Src-linked immunosorbent assay.
A: Puri¢ed GST-Src was run on 8% sodium dodecyl sulfate^poly-
acrylamide gel electrophoresis (SDS^PAGE) and after Western blot-
ting, the membrane was probed with anti-phosphotyrosine (P-Y-20,
1:2000, Santa Cruz), anti-phospho-Y-419 (1:1000, Biosource), and
anti-phospho-Y-530 (1:1000, Biosource) antibodies, as depicted.
B: Calibration of reaction time using 0.1 mg/ml PGT-coated plate
and 4 Wg GST-Src/ml. C: Michaelis^Menten kinetic plot and the
Km value of ATP for GST-Src as was measured by the ELISA as-
say and calculated using the REGRESSION program (Blackwell
Scienti¢c Software, Osney Mead, Oxford, UK).
Table 1
Activity of other selective tyrphostins against GST-Src
Inhibitor Target GST-Src IC50 (WM) (cell-free) Target IC50 (WM) (cell-free)
PP1 Src kinase 0.05 0.05
PP2 Src kinase 0.1 0.1
AG 490 Jak-2 17 ^
AG 538 IGF-1R 2 0.06
AG 825 HER-2 s 100 0.35
AG 1295 PDGFR s 50 0.4
AG 1478 EGFR 0.5 0.005
Fig. 2. A model stereoview of compound 16 in the Lck site. The
compound 1-(4-carboxyphenyl)-3-(4-methylphenyl)-4-amino pyrazolo
[3.4-d] pyrimidine was synthesized and modeled into the PP2 bind-
ing site based on the Lck-PP2 complex (1QPE). The structure dem-
onstrates that the benzoic acid moiety is positioned in the portal
area of the binding site and there is no apparent steric restriction.
The low a⁄nity (IC50 = 1000 WM, data not shown) could not be
correlated with the structure. The ¢gure was prepared using MOL-
SCRIPT program.
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but in practice was found to be a poor binder (IC50 = 1000
nM). Similar ¢ndings were obtained for 18 compounds with
various substitutions. None of these improved a⁄nities over
PP1 or PP2. These unexpected ¢ndings convinced us that the
mode of binding of PP1 within the active site of active Src in
solution is di¡erent from its binding to Hck or from the bind-
ing of PP2 to Lck within the crystal structure, although these
three enzymes are identical in their APPNHP binding sites.
Furthermore, the amino acids involved in PP1 binding in Hck
are identical to those present in the pp60cSrc and Lck ATP
binding sites (Table 4). Since, in the original publication by
Hanke et al., it was claimed that ‘Preliminary studies with PP1
(data not shown) show complex kinetics for inhibition of
LckT’, it is likely that the inhibition of Lck by PP1 is not
ATP competitive. Our ¢ndings, together with this statement,
prompted us to examine in detail the kinetics of inhibition of
GST-Src by PP1.
3.3. PP1 and PP2 are not ATP competitors and are ‘mixed
competitive’ vis-a'-vis the substrate
PP1 and PP2 did not compete with ATP, while the ATP
mimic AMP-PNP was competitive with ATP in the same as-
says (Table 3, Fig. 3). In the ELISA assay and in the radio-
active assay, increasing the concentration of ATP did not
a¡ect the IC50 values for PP1 and PP2, whereas it elevated
the IC50 values of AMP-PNP (Table 3 and Fig. 3A, C). PP1
was also found to be ‘mixed competitive’ with the substrate
(Fig. 3B). The data show that PP1 decreases the rate constant
for product formation, but at the same time increases the
a⁄nity of the enzyme for the substrate [21]. These results
demonstrate that PP1 does not compete with ATP for binding
to active Src, and at the same time is a ‘mixed competitive’
inhibitor with regard to the Src substrate poly(Glu^Tyr) (4:1).
These results suggest that PP1 and PP2 do not bind to active
Src in the same manner as they bind to Hck and Lck, respec-
tively. PP1 and PP2 seem to inhibit Src by binding to an area
of the molecule that does not overlap with the ATP binding
domain. The binding of the inhibitor, however, interferes with
the binding of the substrate, since it is ‘mixed competitive’
(Fig. 3).
3.4. Structure activity considerations for future Src inhibitors
Over the past decade, several classes of potent tyrosine ki-
nase inhibitors that bind to the ATP site (‘ATP mimics’) have
been discovered (for review see [22]). This is in addition to
Table 2
The inhibition of PTKs and Ser/Thr kinases by PP1 and PP2
GST-Src EGFR PDGFR PKA PKB
PP1 50 600 s 50 000 s 50 000 s 50 000
PP2 100 ND s 50 000 s 50 000 s 50 000
The inhibition of various kinases by PP1 and PP2 is described. The
assays were conducted as described in Section 2 and as described in
[31] (for EGFR), [28] (for PDGFR), and [32] (for PKA and PKB).
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Fig. 3. Inhibition of Src by PP1/PP2 is non-competitive with ATP
and ‘mixed competitive’ with substrate. A: Lineweaver^Burk plots
of a radioactive assay of GST-Src. The activities of Src were deter-
mined using the radioactive assay, as described in Section 2. The re-
actions were performed in the presence of poly(Glu^Tyr) (4:1), at a
¢xed concentration, with (80 WM), and varying concentrations of
ATP (5, 10, 20, 50, 100 WM). Each point represents the average of
duplicate values. This is a plot of one of three experiments, all with-
in less than 5% of each other. B: Lineweaver^Burk plots of a radio-
active assay of GST-Src in the presence of ATP (10 WM), at a ¢xed
concentration, and varying concentrations of poly(Glu^Tyr) (4:1)
(10, 20, 40, 80, 160 WM). C: Lineweaver^Burk plots of an ELISA
assay of GST-Src, as described in Section 2. The reactions were per-
formed in the presence of Glu^Tyr (4:1), at a ¢xed concentration,
(coated on the plates), and varying concentrations of ATP (2.5, 5,
10, 30, 100 WM) or AMP-PNP.
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inhibitors that are substrate competitive [23,24] and inhibitors
that compete with both substrate and ATP, namely bi-sub-
strate inhibitors [25,26]. The ATP mimics are hetero-bicyclic
or hetero-tricyclic compounds whose core structure bears
close resemblance to adenine. Not surprisingly, they all bind
at the ATP sites of the tyrosine kinases. The resemblance to
adenine is especially evident in the pyrrolo or pyrazolo pyrim-
idine family of Src kinase inhibitors and the quinazoline in-
hibitors of the epidermal growth factor receptor (EGFR) [27],
which possess 1,4-diaza and 4-amino or anilide hetero substi-
tution patterns that are identical or very similar to adenine.
The quinoxaline inhibitors of the PDGFR possess a 1,3-diaza
substitution [28] but lack the 4-amino moiety, and thus are
less similar to adenine. Indeed, we have previously shown that
bicyclic quinoxalines are ‘mixed competitive’ inhibitors of ac-
tivated PDGFRL vis-a'-vis ATP [29]. Interestingly, all these
inhibitors possess, in addition to the core pharmacophore,
an aryl group, which interacts with a lipophilic pocket near
the ATP binding site. This extra binding seems to be essential
for the potency of the inhibitors and also seems to be the
main factor in their selectivity. This is exempli¢ed by the
aryl at position 3 in the quinazolines, which are selective for
PDGFR [28], and at position 4 in quinoxalines, which are
selective for EGFR [27]. Thus, small di¡erences in the very
highly homologous ATP binding sites of tyrosine kinases have
made it possible to identify selective inhibitors, although a
decade ago many thought this unlikely [30]. All these com-
pounds were discovered mainly through random screening,
guided by the simple rationale that aromatic systems are likely
to substitute for ATP. The recent X-ray studies of Src kinase
family proteins co-crystallized with inhibitors ^ Hck in com-
plex with PP1 [10] and Lck with PP2 [11] ^ revealed the exact
binding mode for these inhibitors in the ATP pocket in the
crystal.
It has also been shown that small changes in ATP compet-
itive inhibitors (like 4-anilinoquinazolines) can modify their
kinetic characteristics leading to dual-site inhibitors that are
competitive with both ATP and substrate [26]. Such experi-
ments demonstrate the proximity of these two subsites. The
relative selectivity of PP1/PP2 towards active Src may be ac-
counted for by their binding to a unique domain close to the
substrate site but removed from the ATP binding domain. It
is, therefore, important to co-crystallize active c-Src with PP1
or PP2 and compare the structure with that of Hck-PP1 and
Lck-PP2. We believe that a substrate competitive inhibitor or
a substrate ‘mixed competitive’ inhibitor may be useful for
generating an inhibitor with strong selectivity for Src. For
therapeutic use, it may be necessary to inhibit Src, but not
Lck or Hck, which have pivotal roles in signaling hemato-
poietic immune cells. The sequences of Src, Lck and Hck at
domains adjacent to the ATP binding sequences show signi¢-
cant di¡erences (Table 4). It is therefore possible that PP1
actually binds to the ATP-adjacent domain. This would ac-
count for the signi¢cant di¡erences in the IC50 values for PP1
for Hck (20 nM), Lck (5 nM), Fyn (6 nM) and Src (170 nM),
as reported by Hanke et al. [19]. These di¡erences may even-
tually be exploited to generate selective Src kinase inhibitors.
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